메뉴 건너뛰기




Volumn 10, Issue 7, 2015, Pages 1116-1117

Cystic brain metastases in NSCLC harboring the EML4-ALK translocation after treatment with crizotinib

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARBOPLATIN; CERITINIB; CRIZOTINIB; ERLOTINIB; PACLITAXEL; CELL CYCLE PROTEIN; EML4 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SERINE PROTEINASE;

EID: 84942881475     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000409     Document Type: Article
Times cited : (13)

References (12)
  • 1
    • 84898936879 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive
    • Malik SM, Maher VE, Bijwaard KE, U.S. Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014 20 2029 2034
    • (2014) Clin Cancer Res , vol.20 , pp. 2029-2034
    • Malik, S.M.1    Maher, V.E.2    Bijwaard, K.E.3
  • 2
    • 84870725524 scopus 로고    scopus 로고
    • Isolated central nervous system progression on crizotinib. An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
    • Chun SG, Choe KS, Iyengar P, Isolated central nervous system progression on crizotinib. An Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 2012 13 1376 1383
    • (2012) Cancer Biol Ther , vol.13 , pp. 1376-1383
    • Chun, S.G.1    Choe, K.S.2    Iyengar, P.3
  • 3
    • 84919771571 scopus 로고    scopus 로고
    • Cystic brain metastasis in non-small cell lung cancer with ALK rearrangement
    • Hayashi H, Okamoto I, Tanizaki J, Cystic brain metastasis in non-small cell lung cancer with ALK rearrangement. J Clin Oncol 2014 32 1 3
    • (2014) J Clin Oncol , vol.32 , pp. 1-3
    • Hayashi, H.1    Okamoto, I.2    Tanizaki, J.3
  • 4
    • 84876354373 scopus 로고    scopus 로고
    • Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement
    • Takeda M, Okamoto I, Nakagawa K, Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 2013 8 654 657
    • (2013) J Thorac Oncol , vol.8 , pp. 654-657
    • Takeda, M.1    Okamoto, I.2    Nakagawa, K.3
  • 5
    • 84892187259 scopus 로고    scopus 로고
    • The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer
    • Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013 8 1570 1573
    • (2013) J Thorac Oncol , vol.8 , pp. 1570-1573
    • Gainor, J.F.1    Ou, S.H.2    Logan, J.3    Borges, L.F.4    Shaw, A.T.5
  • 6
    • 84866934606 scopus 로고    scopus 로고
    • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study
    • Camidge DR, Bang Y-K, Kwak EL, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012 13 1011 1019
    • (2012) Lancet Oncol , vol.13 , pp. 1011-1019
    • Camidge, D.R.1    Bang, Y.-K.2    Kwak, E.L.3
  • 7
    • 84856999699 scopus 로고    scopus 로고
    • Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
    • Katayama R, Shaw AT, Khan TM, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012 4 12 17
    • (2012) Sci Transl Med , vol.4 , pp. 12-17
    • Katayama, R.1    Shaw, A.T.2    Khan, T.M.3
  • 8
    • 84890018871 scopus 로고    scopus 로고
    • Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
    • Gainor JF, Shaw AT, Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013 31 3987 3996
    • (2013) J Clin Oncol , vol.31 , pp. 3987-3996
    • Gainor, J.F.1    Shaw, A.T.2
  • 9
    • 79957487193 scopus 로고    scopus 로고
    • CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
    • Costa DB, Koboyashi S, Pandya SS, CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011 29 e443 e445
    • (2011) J Clin Oncol , vol.29 , pp. e443-e445
    • Costa, D.B.1    Koboyashi, S.2    Pandya, S.S.3
  • 10
    • 84896957081 scopus 로고    scopus 로고
    • Ceritinib in ALK-rearranged non-small-cell lung cancer
    • Shaw AT, Kim DW, Mehra R, Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014 370 1189 1197
    • (2014) N Engl J Med , vol.370 , pp. 1189-1197
    • Shaw, A.T.1    Kim, D.W.2    Mehra, R.3
  • 11
    • 84908569219 scopus 로고    scopus 로고
    • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase study
    • Gadgeel SM, Gandhi L, Riely GJ, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase study. Lancet Oncol 2014 15 1119 1128
    • (2014) Lancet Oncol , vol.15 , pp. 1119-1128
    • Gadgeel, S.M.1    Gandhi, L.2    Riely, G.J.3
  • 12
    • 84911917752 scopus 로고    scopus 로고
    • Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC)
    • suppl; abstr 8047
    • Gettinger SN, Bazhenova L, Salgia R, Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2014 32 suppl; abstr 8047 5s
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Gettinger, S.N.1    Bazhenova, L.2    Salgia, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.